[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xingchen Peng\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,67,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100600647","phase-1-a-clinical-trial-evaluating-il-22bplnp-compound-in-refractory-malignant-solid-tumors-for-safety-tolerability-and-activity-100600647",false,"NCT07100210","A Clinical Trial Evaluating IL-22BP\u002FLNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity","A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of IL-22BP\u002FLNP Compound in Refractory Malignant Solid Tumors","Inclusion Criteria:\n\n1. Male or female patients: aged ≥ 18 years old and ≤ 70 years old;\n2. Patients with histopathologically confirmed, refractory to second-line treatment, advanced recurrent\u002Fmetastatic malignant solid tumors and without standard clinical treatment regimens (such as patients with advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.);\n3. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1;\n4. Expected survival time ≥ 3 months;\n5. More than 28 days since the last chemotherapy\u002Fradiotherapy\u002Fsurgery;\n6. More than 6 weeks since the last use of nitrosoureas or mitomycin C;\n7. Main organ functions are in good condition;\n8. Sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Have participated in other drug clinical trials within 4 weeks;\n2. The tumor is located close to major blood vessels or the trachea;\n3. Patients with uncontrolled cardiac clinical symptoms or diseases, such as heart failure of NYHA class II or above, unstable angina pectoris, having had a myocardial infarction within 1 year, and having clinically significant supraventricular or ventricular arrhythmias that require treatment or intervention.\n4. For female subjects: pregnant or lactating women.\n5. Patients have active tuberculosis, bacterial or fungal infections (≥ grade 2 of NCI-CTCAE 5.0); have active HIV infection, active HBV infection, or HCV infection.\n6. Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders;\n7. Subjects have any active autoimmune diseases or a history of autoimmune diseases (such as, but not limited to: uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or those whose asthma in childhood has been completely relieved and who do not require any intervention in adulthood can be included; subjects with asthma that requires bronchodilators for medical intervention cannot be included).\n8. Subjects are currently receiving immunosuppressive treatment.\n9. Have a history of drug abuse or known medical, psychological, or social conditions, such as a history of alcoholism or drug use.\n10. Known to be allergic, hypersensitive, or intolerant to the studied IL-22BP\u002FLNP (including any excipients). Have a severe allergy history to any drugs, foods, or vaccines in the past, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local allergic necrotizing reaction (Arthus reaction), etc.\n11. From the screening period to 12 months after the completion of drug injection, female subjects have pregnancy plans or the partners of male subjects have pregnancy plans.\n12. According to the investigator's judgment, there are concomitant diseases that seriously endanger patient safety or affect the patient's completion of the study.","ALL","18 Years","70 Years",{"count":20,"type":21},6,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study aims to investigate the safety and efficacy of the IL-22BP\u002FLNP compound in patients with refractory malignant solid tumors, such as advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, and malignant melanoma, who have failed second-line treatment, have advanced recurrence or metastatic malignant solid tumors.",[27,28,29],"Refractory Malignant Solid Tumors","mRNA Vaccine","Interleukin","RECRUITING","2025-12-21",{"date":33,"type":34},"2025-12-29","ACTUAL",{"date":36,"type":34},"2025-01-20",{"date":38,"type":21},"2026-02-20",{"name":40,"class":41},"Xingchen Peng","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100616576","web-based-platform-for-nutrition-management-in-patients-with-cancer-100616576","NCT07307404","Web-based Platform for Nutrition Management in Patients With Cancer","Web-based Platform for Nutrition Management in Patients With Cancer: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Pathologically confirmed malignant tumor;\n* PG-SGA score of 4-9 points;\n* Age: ≥18 years, with an expected survival time of more than 1 year;\n* Possesses adequate cognitive and reading abilities to complete questionnaires and use the APP.\n\nExclusion Criteria:\n\n* Presence of neurological or psychiatric disorders affecting cognitive function, including central nervous system metastasis of tumors;\n* Suffering from conditions severely impacting digestion, metabolism, or food intake;\n* Patients in the cachexia stage or refractory cachexia phase.","80 Years",{"count":52,"type":21},84,[54],"NA","It is crucial to promptly identify nutritional issues in these patients within the community and provide them with dietary guidance, nutritional counseling, and support. This study will be conducted in communities in Chengdu, Sichuan. Community management teams will register oncology patients, collecting information such as demographic data, tumor type, stage, specific treatment plan, treatment hospital, regularity of hospital admissions, and frequency of independent smartphone use. Registered patients will be screened based on inclusion and exclusion criteria. For those who meet the criteria, the community management team will contact them and recommend the use of a dedicated app developed by the research team. An initial nutritional assessment will also be conducted. Patients identified with nutritional risks will be directly referred to the research team's clinical nutritionists for face-to-face consultations. After additional tests, such as body composition analysis, necessary nutritional education and stepwise nutritional interventions will be provided. These patients will also use the app for dietary monitoring and nutritional guidance. For patients without nutritional risks, the app will be recommended for daily questionnaire completion and activity tracking.",[57],"Nutrition",[59],"cancer","2025-12-14",{"date":33,"type":34},{"date":63,"type":21},"2025-12-30",{"date":65,"type":21},"2027-04-30",{"name":40,"class":41},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":42},"100583614","phase-1-a-polyphenol-whole-tumor-cell-vaccine-in-patients-with-advanced-malignant-solid-tumors-100583614","NCT06878612","a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors","A Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n1. Male or female patients aged 18 to 65 years (including borderline values) at screening.\n2. Advanced metastatic malignant solid tumors (skin or limb melanoma\u002Fhead and neck tumors\u002Fsoft tissue tumors, etc.) confirmed histologically or cytologically, with previous failure of second-line or higher treatment (refer to the China Clinical Oncology (CSCO) Melanoma Guidelines 2024, CSCO Head and Neck Tumor Guidelines 2024, and CSCO Bone and Soft Tissue Tumor Guidelines.\n\n   Note: ① Advanced metastatic melanoma: first-line standard treatment includes dacarbazine\u002Ftimozolomide ± platinum ± endo, and dabrafenib + trametinib is recommended if the BRAF V600 mutation is carried. Second-line treatment may be considered with a different drug therapy than first-line treatment, and if PD-1 monoclonal antibody is not used in the first line, pabolizumab or treprotilizumab is recommended in the second line. If tumor reduction is urgently needed, targeted drugs or chemotherapy combination regimens (paclitaxel\u002Falbumin paclitaxel ± platinum ± antivascular drugs) are preferred in the second line. If NRAS mutation is carried, tulolametinib (HL085) is recommended.\n\n   (ii) Advanced metastatic head and neck tumors: first-line standard treatment includes pembrolizumab + cisplatin\u002Fcarboplatin + 5-Fu, pembrolizumab (CPS ≥ 1), cisplatin\u002Fcarboplatin + 5-Fu + cetuximab, cisplatin + docetaxel + cetuximab, and cisplatin\u002Fcarboplatin + paclitaxel ± cetuximab. Second-line or salvage therapy is recommended, such as nabulizumab.\n\n   (iii) Advanced metastatic soft tissue sarcoma: first-line standard treatment includes doxorubicin ± isocyclophosphamide chemotherapy, and second-line treatment is based on the specific type of chemotherapy or amilorotinib targeted therapy.\n3. Presence of at least 1 measurable or evaluable lesion according to RECIST v1.1 criteria.\n4. Eastern Cooperative Oncology Group (ECOG) physical status score: 0 to 2.\n5. Expected survival ≥ 3 months.\n6. Good function of major organs, and the following requirements are met by the examination indexes within 7 days prior to receiving treatment:\n\n   ① Hemoglobin ≥80 g\u002FL; neutrophil count \\>1.5×109\u002FL; platelet count ≥80×109\u002FL;\n\n   ② Total bilirubin ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 × ULN; if there are liver metastases, ALT or AST ≤ 5 × ULN;\n\n   ③ Creatinine (SCr) ≤ 1.5 × ULN or creatinine clearance (CRCI) ≥ 60 mL\u002Fmin (Cockcroft-Gault formula) (see 16.6 Appendix VI);\n\n   ④ Prothrombin time (PT), International Normalized Ratio (INR) ≤ 1.5 x ULN (unless warfarin anticoagulation is being used).\n\n   ⑤ Cardiac function: left ventricular ejection fraction (LVEF) ≥50%.\n7. Able to understand and voluntarily sign a written informed consent before the trial.\n\nExclusion Criteria:\n\n1. Patients with a prior history of other tumors, except for cured and non-recurrent basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical cancer in situ, gastrointestinal intramucosal carcinoma, and other histories of malignancies deemed by the investigator to be eligible for enrollment.\n2. Patients with known concomitant cardiac clinical conditions or diseases that are not well controlled, e.g., New York Heart Association (NYHA) class II or higher heart failure (see 16.5 Appendix V), unstable angina, myocardial infarction within 6 months, supraventricular or ventricular arrhythmias that are clinically significant and require treatment or intervention.\n3. Patients with previous and current objective evidence of asthma, history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, and severely impaired lung function.\n4. Have any uncontrollable clinical disease (e.g., respiratory, circulatory, digestive, neurologic, hematologic, genitourinary, endocrine system disorders) or psychiatric disease (e.g., depression, schizophrenia) or other significant illnesses assessed by the investigator as preventing the provision of informed consent, interfering with the interpretation of the trial results, potentially posing a risk to subjects by participating in this trial, or otherwise otherwise interfere with achieving the purpose of the study.\n5. Have any active autoimmune disease or a history of autoimmune disease including, but not limited to, immune-related neurological disorders, multiple sclerosis, autoimmune (demyelinating) neuropathies, Guillain-Barre Syndrome, myasthenia gravis, systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease including Crohn's disease and ulcerative colitis, autoimmune hepatitis, toxic epidermal necrolysis-relaxation (TEN) or Stevens-Johnson syndrome (except for type I diabetes on stable doses of insulin).\n6. Allergy to the test drug (including any excipients). Prior history of severe allergy to any drug, food, or vaccination, such as anaphylaxis, anaphylactic laryngeal edema, anaphylactic dyspnea, anaphylactic purpura, thrombocytopenic purpura, and localized anaphylactic necrotic reaction (Arthus reaction).\n7. the existence of intradermal injection contraindications: ① injection site inflammation, trauma ulceration. ② severe bleeding, coagulation tendency, platelets or coagulation factors significantly reduced. ③ Any abnormalities or permanent body art (e.g., tattoos) at the vaccination site that, in the opinion of the investigator, would prevent observation of local reactions at the vaccination site.\n8. Participation in other drug or device clinical trials within 3 months prior to screening.\n9. Major surgery (minor surgery such as catheterization, protocol-required biopsy procedures, etc. is not an exclusion criterion) within 4 weeks prior to the first dose of vaccination or less than 14 days of elimination of the effects of surgery or trauma prior to enrollment, radiotherapy, targeted, immune checkpoint inhibitors, interferon, live\u002Flive attenuated vaccines, and other treatments.\n10. Patients who have not recovered to NCI CTCAE ≤ grade 1 for antitumor therapy-related adverse reactions (except alopecia) after previous antitumor therapy.\n11. Subjects on systemic therapy with corticosteroids (\\>10 mg\u002Fday of prednisone or equivalent dose of other glucocorticoids) or other immunosuppressive agents within 14 days prior to the first dose of vaccination. Inhaled or topical steroids and adrenal hormone replacement at doses ≤ 10 mg\u002Fday prednisone efficacy dose are allowed in the absence of active autoimmune disease.\n12. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and syphilis infections, or positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCVAb), HIV antibody, and syphilitic spirochete (TP) antibody test at screening: HBsAg (+) or HBcAb (+), and HBV DNA copy number ≥ 2000 IU\u002FmL (or the lower limit of positive test values at the host research center); HCVAb positive and HCV RNA ≥ ULN at the host research center.\n13. Patient has a history of active tuberculosis (TB) (patients suspected of having active TB need to be examined on chest X-ray, sputum, and excluded by clinical signs and symptoms) or active TB; or severe acute or chronic infection requiring systemic therapy.\n14. History of substance abuse or known medical, psychological, or social conditions such as alcohol or drug abuse.\n15. Pregnant or breastfeeding women with a screening period up to 12 months after the full course of drug injection, a planned pregnancy in a female subject or a planned pregnancy in the partner of a male subject.\n16. Any other factors that, in the opinion of the investigator, make it inappropriate for the subject to enter this trial.","65 Years",{"count":76,"type":21},9,[24],"This project intends to carry out phase I clinical studies on the basis of the previous work, initially exploring the possible effective dose, evaluating its safety and tolerability, with a view to achieving long-term control of the disease, which is expected to provide more options for the treatment of patients with advanced malignant solid tumors. The development of this project will provide new ideas, strategies and theoretical basis for the research and development of whole tumor cell vaccines; at the same time, it is expected to obtain original new drugs with independent intellectual property rights.",[80,81,82],"Polyphenols","Cancer Vaccine","Advanced Solid Tumor",[84,85,86],"polyphenols","whole tumor cell vaccine","advanced solid tumor","2025-06-01",{"date":89,"type":34},"2025-06-05",{"date":91,"type":34},"2025-04-21",{"date":93,"type":21},"2026-12-31",{"name":40,"class":41},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":42},"100588298","phase-1-hydroxychloroquine-sulfate-tablets-for-radiation-induced-oral-mucositis-100588298","NCT06939582","Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis","A Single Center, Open Label Phase II Clinical Trial of Hydroxychloroquine Sulfate Tablets for the Treatment of Radiation Stomatitis and Taste Disturbance in Intensity Modulated Radiotherapy for Head and Neck Cancer","RIOM","Inclusion Criteria:\n\n* Patients pathologically diagnosed with non-metastatic head and neck malignant tumors\n* Aged 18-80 years\n* Eastern Cooperative Oncology Group performance status of ≤2\n* Planning to receive definitive RT or postoperative adjuvant RT\n* Normal liver, kidney and bone marrow function\n* Sign informed consent\n\nExclusion Criteria:\n\n* Those who are known to be allergic to 4-aminoquinoline compounds or have more serious allergic constitution\n* Had a history of head and neck radiotherapy\n* Patients with non head and neck parts in the radiotherapy area\n* Poor oral hygiene or severe periodontitis\n* Suffering from severe kidney disease, severe cardiovascular disease, myasthenia gravis, Parkinson's disease or epilepsy\n* Recently taking or taking diuretics or other drugs known to interact with hydroxychloroquine sulfate tablets\n* Retinopathy\n* Other patients (combined with any serious other diseases) who the investigator believes are not suitable for participation in this study",{"count":104,"type":21},158,[24,106],"PHASE2","Evaluate the safety, tolerance and efficacy of hydroxychloroquine sulfate tablets the prevention and treatment of oral mucositis and dysgeusia in patients undergoing radiotherapy",[109],"Radiation-induced Oral Mucositis","2025-04-26",{"date":112,"type":34},"2025-04-29",{"date":114,"type":34},"2024-12-22",{"date":116,"type":21},"2025-06-20",{"name":40,"class":41},""]